Today’s Stock On Watch: Could Agios Pharmaceuticals Inc Lose Strenght? The Stock Increases A Lot Today

Today's Stock On Watch: Could Agios Pharmaceuticals Inc Lose Strenght? The Stock Increases A Lot Today

The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) is a huge mover today! About 208,396 shares traded hands. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 26.89% since March 15, 2016 and is uptrending. It has outperformed by 21.40% the S&P500.
The move comes after 8 months positive chart setup for the $2.06 billion company. It was reported on Oct, 18 by We have $68.39 PT which if reached, will make NASDAQ:AGIO worth $762.20 million more.

Analysts await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report earnings on November, 3. They expect $-1.44 EPS, down 34.58% or $0.37 from last year’s $-1.07 per share. After $-1.47 actual EPS reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -2.04% EPS growth.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Out of 11 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 6 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 55% are positive. Agios Pharmaceuticals has been the topic of 19 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Roth Capital maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) rating on Monday, November 9. Roth Capital has “Neutral” rating and $75 price target. Roth Capital maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) rating on Wednesday, August 5. Roth Capital has “Hold” rating and $114 price target. The firm has “Hold” rating by Canaccord Genuity given on Friday, August 7. On Monday, November 9 the stock rating was maintained by TH Capital with “Neutral”. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has “Market Perform” rating given on Monday, December 7 by Leerink Swann. SunTrust initiated the stock with “Buy” rating in Wednesday, March 30 report. The firm earned “Neutral” rating on Friday, August 19 by BTIG Research. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Outperform” rating by Northland Capital on Thursday, July 23. On Wednesday, May 18 the stock rating was maintained by Suntrust Robinson with “Buy”. The firm has “Outperform” rating given on Wednesday, May 18 by Credit Suisse.

According to Zacks Investment Research, “Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company’s products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.39 in 2016 Q2. Its up 0.03, from 1.36 in 2016Q1. The ratio increased, as 22 funds sold all Agios Pharmaceuticals Inc shares owned while 37 reduced positions. 18 funds bought stakes while 64 increased positions. They now own 35.06 million shares or 11.59% more from 31.42 million shares in 2016Q1.
Wells Fargo And Mn reported 13,996 shares or 0% of all its holdings. Canada Pension Plan Investment Board holds 0% or 11,000 shares in its portfolio. Guggenheim Limited Liability Corp owns 65,039 shares or 0.01% of their US portfolio. Manufacturers Life Insur The last reported 1,060 shares in the company. The California-based Checchi Advisers Lc has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Swiss Bank accumulated 47,560 shares or 0% of the stock. Principal Fincl Group holds 5,956 shares or 0% of its portfolio. Aperio Grp Lc accumulated 5,572 shares or 0% of the stock. The Kentucky-based Teachers Retirement Systems Of The State Of Kentucky has invested 0.02% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Comml Bank Of New York Mellon Corp owns 108,966 shares or 0% of their US portfolio. Price T Rowe Inc Md holds 0.01% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 831,949 shares. Seven Eight Cap Ltd Limited Liability Company, a New York-based fund reported 22 shares. Creative Planning has invested 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Proshare Advisors Limited Liability Company has invested 0.02% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). The Massachusetts-based Eventide Asset Mngmt has invested 0.77% in Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Insider Transactions: Since April 25, 2016, the stock had 0 insider buys, and 8 sales for $2.91 million net activity. 2,504 shares with value of $93,424 were sold by Cantley Lewis Clayton Jr. on Monday, August 29. The insider Biller Scott sold $1.79M.

More notable recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: which released: “Why Agios Pharmaceuticals Inc Stock Skyrocketed Today” on September 07, 2016, also with their article: “Why Agios Pharmaceuticals Inc. Presented Lower Today” published on June 09, 2016, published: “3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016” on July 03, 2016. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) were released by: and their article: “A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April” published on May 06, 2016 as well as‘s news article titled: “The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January” with publication date: February 06, 2016.

AGIO Company Profile

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its RGD programs, AG-348, which targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment